In a major announcement that sent shockwaves across the pharmaceutical sector, former U.S. President Donald Trump promised a set of 'never-seen-before' tariffs aimed at foreign pharmaceutical companies.
Following the statement, India's Nifty Pharma index plunged by 4.5%, with leading stocks like IPCA Laboratories and Lupin experiencing a sharp 6% decline. Market analysts fear further volatility if these trade tensions escalate.
Investors and companies are now watching closely for official policy documents and statements from both Indian regulatory bodies and international trade partners to assess the full impact of this proposal.
The Indian government is expected to issue a formal response soon. Meanwhile, domestic pharma companies are preparing contingency plans and re-evaluating export strategies to mitigate potential losses.
📢 Stay tuned for more updates as the story develops.